Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adult enteral formula · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Adult enteral formula | OTHER | - |
Inclusion Criteria: * signed and dated informed consent * 18-75 years of age * history of type 2 diabetes * males and non-pregnant, non-lactating females Exclusion Criteria: * subject uses insulin for glucose control * significant cardiovascular event \<12 weeks prior to study entry * active mali...
Adult enteral formula is a nutritional product being studied for use in Diabetes Mellitus Type 2. It is designed to be consumed by adults with this condition, and a clinical trial has evaluated glucose and insulin responses after consuming diabetes-specific versus standard nutritional formulas.
Adult enteral formula is developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker ABT. The company is conducting clinical research to evaluate the formula's effects in people with Type 2 diabetes.
Adult enteral formula is in Phase 3 clinical development. It is an investigational product, meaning it has not been approved by regulatory authorities. One Phase 3 trial has been completed to assess its effects in patients with Type 2 diabetes.
Adult enteral formula has been studied in one completed Phase 3 trial, NCT00540488, titled 'Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas'. The trial enrolled 54 participants in the United States and was randomized and double-blind.
Adult enteral formula is a diabetes-specific nutritional formula, distinct from standard nutritional formulas. A clinical trial compared glucose and insulin responses in subjects with Type 2 diabetes consuming diabetes-specific versus standard formulas, indicating the two are different products.